Company History

Mayne Pharma has over 160 years of history in pharmaceutical development and manufacturing.

Mayne Pharma Historical Images

1970s	1980s	1990s	2000s
Development of enteric coated levodopa (Prodopa™). Betadine™ licensed to Sanofi-Aventis Australia from Mundipharma. Development of enteric coated erythromycin (Eryc™). FDA approval and first US sales of Eryc™ by Warner Lambert (Chilcott).	Salisbury site acquired in 1983 by F H Faulding & Co Limited. Development of delayed release Doxycycline capsules (Doryx™). Development of enteric coated aspirin (Astrix™). Development of Sustained release theophylline (Austyn™). WF Scammell Research Centre opened at Salisbury.	Development of taste-masking technology (Cleantaste™). Development of sustained release morphine (Kadian™). Development of Taste Masked paracetamol (Nopap™). Development of Taste Masked Ambroxol.	Super-bioavailability (SUBA™). Mayne Group acquires F H Faulding & Co Limited. Development of delayed release Doxycycline tablets (Doryx™). Mayne group demerges into Symbion Health and Mayne Pharma. Hospira Inc. acquires Mayne Pharma. Development of the Doryx™ 150mg tablet. Mayne Pharma International. acquired by Halcygen Halcygen changes its name to Mayne Pharma Group Limited

Related Content